Member Info for bapuk

I’ve seen a few posters today deride the low £ from sales to BC in Feb 21...but since the first shipment of the Genedrive kit that was RNSed on 17 Feb, why would one expect huge sales figures in just half a month (the shortest month in the year at that)!

Surely if sales figures for the whole of March were publicised in April, it would not be a linear increase ...neither 400k, nor 800k but some multiples of this...

It’s just unfortunate that their half year results had to come out now, and not in a month or so, when a much healthier sales trajectory could be announced,

Imho
Bapuk

Tried buying at 61p but couldn’t so made do with 73p instead ...bargain!
Gla
Bapuk

Who sold at 60p?!

I tried buying at that price but could only top up at 73p, which I did !

Gla
Bapuk

What does Establishment Registration and Device Listing mean, is that Approved now?!
Thanks
Bapuk

...to GDR’s market cap?!

As GDR’s certainly not being valued for all that additional business, chiefly
1) the AIHL test
2) US department of defense contract for this year (we should be hearing about that any time soon)
3) Hep C assay

I’m in a rush but I’m sure someone else can point out the sums/value currently not being ascribed to all of this...

And these products/tests are ready now, not pie in the sky!

Imho
Bapuk

And there’s no smoke without fire ...!

Gla
Bapuk

I’m invested in 4 of the companies mentioned there, inc MhC , looking like a blue day for all!
I think March is going to be a big month for all the covid testing companies in terms of contracts/ramping up production and sales etc

Imho
Bapuk

I’m invested in 4 of the companies mentioned there, inc MhC , looking like a blue day for all!
I think March is going to be a big month for all the covid testing companies in terms of contracts/ramping up production and sales etc

Imho
Bapuk

Yes, but how does one know it they increased their holding via the placing at 1.75p versus buying on the open market at prevailing sp?

Thanks
Bapuk

Dear all

Referring back to the Genedrive POC test mentioned in the 22 Oct 2020 rns, have we heard any updates since then? We only have a few weeks to go till the end of Q1, lots of news on all fronts to look forward to....

Stupid question to be asking at this stage I know, but does anyone understand whether the Genedrive POC test is considered to be PCR test, or is it an antigen test like the lateral flow tests currently being used by the Nhs eg Innova etc? One of the sky news headline articles today was in regard to the accuracy of PCR tests versus the speed/point of care convenience of lateral flow tests ...will the Genedrive POC test be the best of both worlds, which will give it a unique advantage over eg POC tests being developed by ODX & partners/AVCT/NCYT etc?

Hoping that by assessing the pros and cons of the various POC tests, will be more likely to be able to predict which ones US/Europe/Uk/rest of world are likely to purchase in bulk...

Thanks for opinions in advance,
Bapuk

Thu, 22nd Oct 2020 07:00

RNS Number : 8438C
Genedrive PLC
22 October 2020



genedrive plc

("genedrive" or the "Company")



Point-of-Care solution to detect SARS-CoV-2 virus in saliva

Development update



genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company's Point-of-Care ("POC") solution for COVID-19 testing and is now generating very promising analytical data aligned to market requirements.



The Genedrive® SARS-CoV-2 POC Kit is being designed to detect SARS-CoV-2, the virus causing COVID-19, amplified directly from a saliva sample without the need to extract viral RNA. This expands the potential use areas of the product and importantly, allows for rapid testing to be performed while a patient is present. When running on the Genedrive® POC device the chemistry is detecting a positive SARS-CoV-2 sample in approximately 15 minutes, with fully negative samples taking just over 20 minutes to resolve. The limit of detection is in line with the UK's MHRA Target Product Profile sensitivity requirements.



The Genedrive SARS-CoV-2 POC Kit follows a similar workflow that has already been validated in the Company's Genedrive® HCV-ID Kit which received WHO pre-qualification earlier this year.



The Company is targeting the end of the calendar year for completion of preliminary product evaluations, with full release of the final CE Marked system in Q1 2021 allowing for thorough clinical testing requirements. Additionally, the Company is working to progress to a version 2 of the product, which would accept a similar freeze-dried PCR bead format previously developed for the high throughput Genedrive® 96 SARS-CoV-2 Kit. This will allow for lower production costs and highly scalable manufacturing capacity.

Courtesy of DJM1 earlier:

BREA, California, June 15, 2020 /PRNewswire/ -- Beckman Coulter today announced that its Access SARS-CoV-2 IgG assay is now available in markets accepting the CE Mark. The company has already shipped tests to more than 400 hospitals, clinics and diagnostics laboratories in the U.S. and has begun shipping to customers globally. Beckman Coulter has more than 16,000 immunoassay analyzers worldwide and has ramped its manufacturing to deliver more than 30 million tests a month.

DJM1, that’s great distribution news, should post it also under a new header/thread for all to see it easily,

Thanks
Bapuk

It may not get to 500p...but even 200-300p is a huge ROI for those buying at current sp ( I appreciate not for those LTH who bought in that price range last year, like me, unless they averaged down in ensuing months) .

Look at today’s transformational news- surely justifies a sp/mcap rise of more than 20-25%..?

After the 8:30-9am retrace, let’s see where the sp goes, esp when the yanks wake up to this news pertaining to a product in their market...

Imho
Bapuk

500p Is achievable ....depending on sales volume/profit.
Look at how ridiculously low our mcap is compared to the other covid test companies, as others have pointed out in the previous days and weeks. We only have 63 million shares in issue , so sp rise likely to be much steeper than company with many more shares in issue.

But first 100p then 200p etc etc .::and it won’t go up in a straight line or all in one day ...just look at Ncyt’s sp movement around the same time last year, and in the weeks that followed...

Imho
Bapuk

This is the start of rerate- in the past months, Gdr sp/mcap has been priced for the company to fail (not even taking into account the likely profit from its non-covid business).

From today, it should be priced on the basis of sales (from the commercial arrangement with BC, although we aren’t given that price sensitive info at this stage)... just compare this RNS today with AVCT’s RNS from today....behind the curve,

IMHO
Bapuk

Dear all

Putting aside the disappointment about Covid test sales /lack thereof (and concerns that the window of opportunity to make those sales is narrowing with vaccines on the horizon), surely the mcap of GDR is so low now that there is little downside risk in buying at 50p .... Just considering GDRs has these 3 other near-term/ current revenue streams, from the 17 Nov rns:
· HCV test

· AIHL test CE-marked and distributor contracted for UK product launch

· Framework contract with the DoD increased by $2.0m

Plus cash in bank of £8mil as mentioned in that RNS....

It won’t take much to ignite the sp, with so little being factored into current mcap,

IMHO
Bapuk

Thanks. And i forgot to say of course that there is so much need for repeat/ongoing testing of just any one country’s population that even if GDR are later to the market than other PoC tests , there is enough room at the table for multiple companies to make big sales/revenues from testing ...
IMHO
Bapuk

Q1 is not so far away (yes, range of Jan to March). But that’s just the POC Device side of things, the Lab based test sales /approvals are expected imminently ...

And forget vaccine/uptake issues, there will be ongoing worldwide and Daily need for PoC testing to take place beyond spring, just to reassure workplaces/travel/leisure/schools etc that any individual is covid free before being allowed to enter premises/plane/cruise ship etc ....

IMHO
Bapuk

Dear Chiron

Didn’t you mean false positives (rather than false negatives) in that statement “ PCR is actually giving us far too many repeated false negatives by amplifying viral RNA when patients are no longer infectious but still have viral RNA in their system”?

Thanks
Bapuk

Serious movement in sp and volume!
Don’t know if this is FOMO from all the sideliners who now think that the big news anticipated is about to be released or daytraders selecting this as a hot buy for the day/week....

Either way, exciting for holders!
Gla
Bapuk